Form 4: MiNK Therapeutics Director Granted Stock Options

MiNK Therapeutics director Peter Behner was granted 5,395 stock options with an exercise price of $11.12, vesting on February 2, 2026.

Summary

• Peter Behner, a Director of MiNK Therapeutics, Inc. (INKT), was granted 5,395 stock options.
• The stock options have an exercise price of $11.12 per share.
• The options were granted on January 2, 2026, and have an expiration date of January 2, 2036.
• The options vest on February 2, 2026, contingent upon Mr. Behner's continued service on the Issuer's Board of Directors through that date.
• Following this transaction, Mr. Behner beneficially owns 5,395 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a routine compensation event that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.

Risks

• The vesting of the stock options is conditional on the reporting person's continued service on the Board of Directors through February 2, 2026.

Future Outlook

The grant of stock options is a standard compensation practice intended to incentivize long-term commitment and performance from the director, aligning their future financial interests with the company's success.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to attract and retain talent and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of non-cash compensation for directors across the biotech industry, similar to practices at companies like Moderna or BioNTech, aiming to link director performance to shareholder value.
• The vesting schedule, contingent on continued service, is typical for such grants, ensuring retention and commitment from board members.

Related Party Transactions

• The grant of stock options to Peter Behner, a Director, constitutes a related party transaction, which is a standard form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term financial interests with shareholder value creation, potentially leading to more focused governance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on February 2, 2026, provided the director continues to serve on the Board.

Key Dates

Keywords

MiNK Therapeutics, INKT, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant